Psychopharmacology

Peter J. Weiden, MD, discusses the latest Cobenfy data and implications for schizophrenia treatment.

Transneural Therapeutics launches innovative neuroplastogens to revolutionize treatment for neuropsychiatric diseases, promising safer, effective alternatives to psychedelics.

New research reveals that discontinuing long-term benzodiazepine therapy may increase risks of mortality and other adverse outcomes, challenging common assumptions.

How can psychiatric professionals and pharmacists best work together to improve patient care? One pharmacist shares his thoughts.

Without the scaffolding of the REMS requirement for clozapine, how can you best utilize this treatment?

How can you best transition patients to Cobenfy if they are already taking an antipsychotic medication?

Joseph Goldberg, MD, discusses the recent joint statement on evidence-based medicine and psychotropic safety.

Learn more about recent research into adolescent mental health, including a pilot study testing the use of short-term trauma stabilization techniques with escitalopram.

Dennis S. Charney, MD, celebrates the 40th anniversary of Psychiatric Times discussing the history of psychiatry and where he hopes the future lies.

A recent meta-analysis compares efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for adults with ADHD.

Determining risks outweigh the benefits, the FDA is removing the clozapine REMS requirement.

Here are 10 things to consider when treating a patient with mood disorders.

Here are highlights from this week in Psychiatric Times, including trial updates and thoughts on the history of the antimedication movement.

Antipsychiatry’s animus toward psychiatric medication has both ancient and modern parallels.

What are the top 6 disappointing psychopharmacological updates from the past year? We rank the top 6.

Here are highlights from this week in Psychiatric Times, including conference updates and trial news.

A 52-week study presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update offered a promising new approach to schizophrenia treatment.

A 52-week study presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update offered a promising new approach to schizophrenia treatment.

Unlocking peak performance starts with the mind—Wilsa Charles Malveaux, MD, MA, FAPA, breaks the stigma around mental health in sports.

Learn more about the findings from the first 3 EMERGENT trials, and their use in the 4th and 5th trials, presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update.

With an FDA Breakthrough Therapy Designation, what are the next steps for MM-120?

A new phase 2 trial reveals a novel antidepressant delivers rapid symptom relief for major depressive disorder, with patients experiencing significant improvement within just hours of their first dose.

MindMed has announced the first patient has been dosed in its phase 3 study Panorama.

Here are highlights from this week in Psychiatric Times, including trial updates and a new approach to treating a surprising condition.

Learn more about Sports Psychiatry Section Editor Wilsa M. S. Charles Malveaux, MD, MA, FAPA, and her path to sports psychiatry.

How have pharmaceutical treatments for psychiatric conditions changed in 40 years?

Check out these updates on research including major depressive disorder (MDD).

What patients are at risk when taking SSRIs?